ArticleBMC anesthesiology2025
Liposomal bupivacaine: a delay rather than elimination of rebound pain in mouse postoperative model.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLiposomal bupivacaine (LB) provides prolonged analgesia, but it remains unclear whether it prevents rebound pain or merely delays its onset. This study investigated the effect of LB on rebound pain in a mouse model of peripheral nerve block to determine whether its resolution results in a pain response exceeding that of unblocked controls.
methodsMethylene blue staining was employed to compare the success rate of nerve stimulator-guided versus anatomical landmark-based techniques for combined sciatic and femoral nerve blockade.Postoperative rebound pain following liposomal bupivacaine administration under nerve stimulator guidance was assessed at multiple time points using von Frey and Hargreaves tests. Histological analyses of perineural inflammation and Wallerian degeneration were conducted on postoperative days 2 and 28.
resultsNerve stimulator-guided blocks had high success rates (sciatic: 93.3%, P=0.035; femoral: 73.3%, P=0.030).LB extended thermal (24h, P<0.05) and mechanical (36h, P<0.05) analgesia. Transient thermal rebound pain occurred at 48h (P=0.003), but no mechanical rebound was observed. LB group showed significantly more severe Wallerian degeneration and Neural inflammation in both the sciatic and femoral nerves compared to the S group at day 2 (P<0.05).
conclusionsLiposomal bupivacaine did not prevent rebound pain but merely delayed its onset in a mouse model of combined sciatic and femoral nerve block.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.